BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association ...

First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 (781) 357-4000 (Registrant's telephone number, including area code) | Securities registered pursuant to Secti ...

Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Dr. Dugel concluded, "I believe the Company has made outstanding progress over the last several months, with the initiation of the Phase 3 SOL-1 study with AXPAXLI in wet AMD and successful financings that raised more than $440 million in gross proceeds from existing and new top tier health ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Peter Kaiser - Chief Medical Advisor, Retina Conference Call Participants Jon Wolleben - JMP Yi Chen - H.C. Wainwright Operator Good day. Thank you for standing by. Welcome to the Third Quarter 2023 Ocular Therapeutix Earnings Conference Call. At this time, all participants are in a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 24 Cro ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2023 Earnings Call Transcript August 7, 2023 4:30 PM ET Company Participants Antony Mattessich - President & CEO Donald Notman - CFO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Conference Call Participants Dane Leone - RJF Jon Wolleben - JMP Joe Catanzaro - Piper Sandler Colleen Kusy - Baird Kelly Shi - Jefferies Tara Bancroft - TD Cowen Chaitanya G - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR Delaware 20-5560161 (781) 357-4000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Commo ...

• One of most common, severe diabetes complications; leading cause of blindness in working-age population *per planned protocol dosing Sources: Eye care of the patient with diabetes mellitus. American Optometric Association, Second Edition; Market Scope - 2022 Retinal Pharmaceuticals Market Report, Global Analysis 2021-2027; Market Scope Q2-2022 US Retina Quarterly Update; AAO DR Preferred Practice Pattern; JAMA Ophthalmol. 2021;139(9):946-955 (PANORAMA); Arcadu F, et al. NPJ Digit Med. 2019;2:92. • Diabeti ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Rabia Ozden - Chief Medical Officer Steve Meyers - Senior Vice President of Commercial Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Tara Bancroft - Cowen Colleen Kusy - Baird Yi Chen - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator ...